Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

Key Points

• Enliven Therapeutics' CFO, Benjamin Hohl, sold 3,250 shares at an average price of $20.46, reducing his stake by 12.38% to 23,000 shares valued at approximately $470,580.
• The company's stock is currently priced at approximately $19.32 with a market cap of $948.03 million, and analysts have set a consensus price target of $41.20 for the stock.
• In recent analyst reports, Goldman Sachs initiated coverage on Enliven Therapeutics with a "buy" rating and a target price of $37, while HC Wainwright raised its target to $48.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $20.46, for a total value of $66,495.00. Following the sale, the chief financial officer directly owned 23,000 shares in the company, valued at $470,580. This trade represents a 12.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, July 10th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.66, for a total value of $22,660.00.
• On Friday, June 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.91, for a total value of $67,957.50.
• On Tuesday, May 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.18, for a total value of $52,585.00.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded down $0.08 during trading hours on Friday, hitting $18.73. The company had a trading volume of 490,125 shares, compared to its average volume of 376,154. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The company has a market capitalization of $919.08 million, a price-to-earnings ratio of -9.76 and a beta of 0.93. The firm's 50 day moving average is $20.68 and its 200 day moving average is $20.10.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Jones Trading reduced their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. HC Wainwright increased their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 price target on the stock. Finally, Robert W. Baird increased their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Enliven Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $41.20.

Institutional Trading of Enliven Therapeutics

Several large investors have recently modified their holdings of the business. FMR LLC grew its stake in shares of Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after acquiring an additional 199,692 shares in the last quarter. Polar Capital Holdings Plc grew its stake in shares of Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after acquiring an additional 1,739,668 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Enliven Therapeutics by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock valued at $44,452,000 after acquiring an additional 55,283 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock valued at $30,001,000 after acquiring an additional 290,153 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its stake in shares of Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock valued at $21,877,000 after acquiring an additional 135,969 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.